Volume 14, Issue 1 (3-2026)                   JoMMID 2026, 14(1): 17-23 | Back to browse issues page

Ethics code: IR.ABADANUMS.REC. 1399.186

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eghdampanah Foumani T, Kamyari N, Shadrvan M M, Khishvand F, Shahroud Dezful F, Kanani K, et al . Evaluation of Diagnostic Markers in Neurological Patients with COVID-19. JoMMID 2026; 14 (1) :17-23
URL: http://jommid.pasteur.ac.ir/article-1-751-en.html
Evaluation of Diagnostic Markers in Neurological Patients with COVID-19
Tina Eghdampanah Foumani , Naser Kamyari , Mohammad Mehdi Shadrvan , Fatemeh Khishvand , Fatemeh Shahroud Dezful , Khadijeh Kanani , Atefeh Zahedi , Sara Mobarak , Esmat Radmanesh *
Department of Physiology, Abadan University of Medical Sciences (AUMS), Abadan, Iran
Abstract:   (1024 Views)
Introduction: The interaction between COVID-19 and pre-existing neurological diseases remains poorly understood, highlighting the need to identify key prognostic markers. This study aimed to characterize the clinical and laboratory profiles and identify predictors of peripheral oxygen saturation (SpO₂) in hospitalized patients with pre-existing neurological disorders and COVID-19. Methods: This retrospective observational study included 128 hospitalized patients with pre-existing neurological disorders and confirmed COVID-19 at Taleghani Educational Hospital in Abadan, Iran, from March 2020 to March 2022. Demographic, clinical, and laboratory data were extracted from the Hospital Information System and patient files. Results: On average, patients exhibited elevated levels of key laboratory markers, including renal (creatinine, BUN), hepatic (ALP, direct bilirubin, AST, ALT), coagulation (PT, aPTT, INR), and inflammatory (ESR) markers. The mean peripheral oxygen saturation (SpO₂) was below the normal range (91.71 ± 7.88%). Multivariable linear regression revealed that in-hospital mortality (B = −5.93; P < 0.001), higher respiratory rate (B = −0.10 per breath/min; P = 0.03), and intubation (B = −5.58; P = 0.001) were significantly associated with lower SpO₂ levels. Conclusion: In this cohort of neurological patients with COVID-19, dysregulation of renal, hepatic, and coagulation markers was common. Critically, lower SpO₂ levels were observed in patients with adverse outcomes, including mortality, respiratory distress, and the need for mechanical ventilation. These findings underscore the importance of monitoring these specific biomarkers and SpO₂ to improve risk stratification and guide clinical management in this high-risk patient population.
 
Keywords: Biomarkers, Coagulation markers, COVID-19, Liver markers, Neurological disorders, Renal markers, SpO₂
Full-Text [PDF 453 kb]   (187 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2025/07/17 | Accepted: 2026/03/10 | Published: 2026/03/8
References
1. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023; 14: 1125246. [DOI:10.3389/fimmu.2023.1125246] [PMID] [PMCID]
2. Mir T, Almas T, Kaur J, Faisaluddin M, Song D, Ullah W, et al. Coronavirus disease 2019 (COVID-19): Multisystem review of pathophysiology. Ann Med Surg (Lond). 2021; 69: 102745. [DOI:10.1016/j.amsu.2021.102745] [PMID] [PMCID]
3. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID 19): comprehensive review of clinical presentation. Front Public Health. 2020; 8: 582932. [DOI:10.3389/fpubh.2020.582932] [PMID] [PMCID]
4. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18 (5): 459-80. [DOI:10.1016/S1474-4422(18)30499-X] [PMID] [PMCID]
5. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77 (6): 683-90. [DOI:10.1001/jamaneurol.2020.1127] [PMID] [PMCID]
6. Mahdizade Ari M, Mohamadi MH, Shadab Mehr N, Abbasimoghaddam S, Shekartabar A, Heidary M, et al. Neurological manifestations in patients with COVID-19: a systematic review and meta-analysis. J Clin Lab Anal. 2022; 36 (5): e24403. [DOI:10.1002/jcla.24403] [PMID] [PMCID]
7. Ghaderi S, Olfati M, Ghaderi M, Hadizadeh H, Yazdanpanah G, Khodadadi Z, et al. Neurological manifestation in COVID-19 disease with neuroimaging studies. Am J Neurodegener Dis. 2023; 12 (2): 42-84.
8. Wang H, Lu J, Zhao X, Qin R, Song K, Xu Y, et al. Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures. Neurol Sci. 2021; 42 (12): 4913-20. [DOI:10.1007/s10072-021-05616-1] [PMID] [PMCID]
9. Shao SC, Lai CC, Chen YH, Chen YC, Hung MJ, Liao SC. Prevalence, incidence and mortality of delirium in patients with COVID-19: a systematic review and meta-analysis. Age Ageing. 2021; 50 (5): 1445-53. [DOI:10.1093/ageing/afab103] [PMID] [PMCID]
10. Ibnouf AAO, Khalil MH, Khalid R, Elshibli EM, Elsayed O, Fadl-Elmula I. Blood markers (lymphocyte percentages, neutrophils, CRP and ESR) can help in prioritizing rRT-PCR test for suspected COVID-19 patients in countries with limited health resources. Pan Afr Med J. 2020; 37: 331. [DOI:10.11604/pamj.2020.37.331.25180] [PMID] [PMCID]
11. Devreese KMJ. COVID-19-related laboratory coagulation findings. Int J Lab Hematol. 2021; 43 (Suppl 1): 36-42. [DOI:10.1111/ijlh.13547] [PMID] [PMCID]
12. Liakina V, Stundiene I, Milaknyte G, Bytautiene R, Reivytyte R, Puronaite R, et al. Effects of COVID-19 on the liver: the experience of a single center. World J Gastroenterol. 2022; 28 (39): 5735-49. [DOI:10.3748/wjg.v28.i39.5735] [PMID] [PMCID]
13. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97 (5): 829-38. [DOI:10.1016/j.kint.2020.03.005] [PMID] [PMCID]
14. Mukandala G, Tynan R, Lanigan S, O'Connor JJ. The effects of hypoxia and inflammation on synaptic signaling in the CNS. Brain Sci. 2016; 6 (1): 6. [DOI:10.3390/brainsci6010006] [PMID] [PMCID]
15. Adingupu DD, Soroush A, Hansen A, Twomey R, Dunn JF. Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19. J Neurol. 2023; 270 (7): 3303-14. [DOI:10.1007/s00415-023-11767-2] [PMID] [PMCID]
16. Dehnavi AZ, Salehi M, Ahmadi MA, Asgardoon MH, Ashrafi F, Ahmadinejad N, et al. Clinical, laboratory and imaging characteristics of hospitalized COVID-19 patients with neurologic involvement; a cross-sectional study. Arch Acad Emerg Med. 2022; 10 (1): e10.
17. Alshehri NN, AlQahtani MA, Riaz F, Mahmood SE, Ahmad A, AbdelGhaffar NF, et al. Neurological manifestations and clinical outcomes of patients with COVID-19 in the Aseer region, Saudi Arabia. Int J Environ Res Public Health. 2023; 20 (5): 3848. [DOI:10.3390/ijerph20053848] [PMID] [PMCID]
18. Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, et al. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 33 (7): 990-5. [DOI:10.1097/MEG.0000000000001817] [PMID] [PMCID]
19. Boregowda U, Aloysius MM, Perisetti A, Gajendran M, Bansal P, Goyal H. Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2020; 7: 431. [DOI:10.3389/fmed.2020.00431] [PMID] [PMCID]
20. Bobermin LD, Quincozes-Santos A. COVID-19 and hyperammonemia: potential interplay between liver and brain dysfunctions. Brain Behav Immun Health. 2021; 14: 100257. [DOI:10.1016/j.bbih.2021.100257] [PMID] [PMCID]
21. Qiu F, Wu Y, Zhang A, Xie G, Cao H, Du M, et al. Changes of coagulation function and risk of stroke in patients with COVID-19. Brain Behav. 2021; 11 (6): e02185. [DOI:10.1002/brb3.2185] [PMID] [PMCID]
22. Dhamoon MS, Thaler A, Gururangan K, Kohli A, Sisniega D, Wheelwright D, et al. Acute cerebrovascular events with COVID-19 infection. Stroke. 2021; 52 (1): 48-56. [DOI:10.1161/STROKEAHA.120.031668] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.